BiotechTube
Axplora

Axplora

Lyon, France· Est.
axplora.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Axplora is a major global CDMO and API supplier formed in 2021, leveraging the legacy and assets of its acquired entities like Novasep and Farmabios. The company boasts a significant operational footprint with over 2,000 employees across three continents, specializing in the development and manufacturing of complex small molecules, including oncology payloads for ADCs and metabolic disorder treatments. Under CEO Martin Meeson, Axplora is executing a clear growth strategy, marked by substantial capital investments in high-demand therapeutic areas to solidify its position as a technologically advanced partner in the pharmaceutical supply chain.

OncologyMetabolic Disorders

Technology Platform

Integrated CDMO and API manufacturing platform with specialized expertise in complex small molecule synthesis, chromatography, high-potent API (HPAPI) handling, and scale-up. Strategic focus on ADC payload and GLP-1 agonist manufacturing technologies.

Funding History

1
UndisclosedUndisclosed

Opportunities

The booming markets for GLP-1 receptor agonists and Antibody-Drug Conjugates (ADCs) represent massive, near-term growth opportunities for Axplora's specialized manufacturing services.
Furthermore, the ongoing trend of pharmaceutical outsourcing and the need for reliable, global API supply chains position the company as a critical partner for both generic and innovative drug developers.

Risk Factors

Key risks include execution risk associated with integrating multiple acquired sites and teams, significant regulatory compliance exposure across ten global manufacturing facilities, and the capital investment risk that demand for newly built ADC and GLP-1 capacity may not meet projections due to market or competitive pressures.

Competitive Landscape

Axplora competes in the fragmented but consolidating global CDMO and API supply market. Key competitors include large public CDMOs like Lonza, Catalent, and Samsung Biologics (though more in biologics), as well as specialized small molecule CDMOs like Cambrex, Sterling Pharma Solutions, and CordenPharma. Its steroid API business under Farmabios also faces competition from other specialty generic API manufacturers.

More companies in Small Molecule Drugs →More companies in France →